Review
doi: 10.2174/187152010794728657.Evolving therapies and FAK inhibitors for the treatment of cancer
Affiliations
- PMID:21291406
- PMCID: PMC3274818
- DOI: 10.2174/187152010794728657
Item in Clipboard
Review
Evolving therapies and FAK inhibitors for the treatment of cancer
Kelli Bullard Dunn et al. Anticancer Agents Med Chem.2010 Dec.
Display options
Format
Display options
Format
Abstract
Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Conflict of interest statement
Dr. Vita Golubovskaya discloses potential conflict of interest with CureFAKtor Pharmaceuticals.
Figures
Activation of an RTK induces dimerization and downstream phosphorylation of non-receptor tyrosine kinases. Major signaling cascades include the RAS/RAF/MAPK pathway, MEK pathway, and the PI3kinase/AKT pathway. (Adapted by permission from Macmillan Publishers Ltd:Nature Reviews Cancer, Zhu & Parada,Nature Reviews Cancer, 2002, 2: 616–626, copyright 2002.)
Progression through each phase of the cell cycle is regulated by cyclin/CDK interactions. (Copyright of Renaic, with kind permission of Renaic Corporation and Sysmex Corporation.)www.sysmex-lifescience.com
FAK plays a key role in a signaling cascade that can lead to some of the tumorigenic properties of cancer cells. FAK activation induces cell proliferation, motility, survival, invasion and metastasis. SABiosciences.www.sabiosciences.com
Similar articles
- Focal adhesion kinase as a cancer therapy target.Golubovskaya VM.Golubovskaya VM.Anticancer Agents Med Chem. 2010 Dec;10(10):735-41. doi: 10.2174/187152010794728648.Anticancer Agents Med Chem. 2010.PMID:21214510Free PMC article.Review.
- Targeting focal adhesion kinase in cancer-part I.Golubovskaya VM.Golubovskaya VM.Anticancer Agents Med Chem. 2010 Dec;10(10):713. doi: 10.2174/187152010794728693.Anticancer Agents Med Chem. 2010.PMID:21348852No abstract available.
- Targeting focal adhesion kinase in neuroblastoma.Gillory L, Beierle EA.Gillory L, et al.Anticancer Agents Med Chem. 2010 Dec;10(10):714-21. doi: 10.2174/187152010794728684.Anticancer Agents Med Chem. 2010.PMID:21269252Free PMC article.Review.
- The role of FAK in tumor metabolism and therapy.Zhang J, Hochwald SN.Zhang J, et al.Pharmacol Ther. 2014 May;142(2):154-63. doi: 10.1016/j.pharmthera.2013.12.003. Epub 2013 Dec 9.Pharmacol Ther. 2014.PMID:24333503Free PMC article.Review.
- Targeting FAK in anticancer combination therapies.Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC.Dawson JC, et al.Nat Rev Cancer. 2021 May;21(5):313-324. doi: 10.1038/s41568-021-00340-6. Epub 2021 Mar 17.Nat Rev Cancer. 2021.PMID:33731845Free PMC article.Review.
Cited by
- Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP, Bai J.Ji HF, et al.J Cancer Res Clin Oncol. 2013 Mar;139(3):429-35. doi: 10.1007/s00432-012-1342-8. Epub 2012 Nov 11.J Cancer Res Clin Oncol. 2013.PMID:23143646
- The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, Tovari J, Waizenegger IC, Dome B, Hegedus B.Laszlo V, et al.J Mol Med (Berl). 2019 Feb;97(2):231-242. doi: 10.1007/s00109-018-1725-7. Epub 2018 Dec 11.J Mol Med (Berl). 2019.PMID:30539198Free PMC article.
- Emerging roles of focal adhesion kinase in cancer.Tai YL, Chen LC, Shen TL.Tai YL, et al.Biomed Res Int. 2015;2015:690690. doi: 10.1155/2015/690690. Epub 2015 Mar 31.Biomed Res Int. 2015.PMID:25918719Free PMC article.Review.
- Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis.Jenardhanan P, Mathur PP.Jenardhanan P, et al.Spermatogenesis. 2015 Jan 26;4(2):e979113. doi: 10.4161/21565562.2014.979113. eCollection 2014 May-Aug.Spermatogenesis. 2015.PMID:26413395Free PMC article.Review.
- The increased adhesion of tumor cells to endothelial cells after irradiation can be reduced by FAK-inhibition.Nguemgo Kouam P, Bühler H, Hero T, Adamietz IA.Nguemgo Kouam P, et al.Radiat Oncol. 2019 Feb 4;14(1):25. doi: 10.1186/s13014-019-1230-3.Radiat Oncol. 2019.PMID:30717801Free PMC article.
References
- American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society; Atlanta: 2010.
- Heffler M, Golubovskaya V, Bullard Dunn KM. Evolving molecular therapies and their applications to surgical oncology. ACS Surg Principles Pract. 2010 (in press)
- Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–9. - PubMed
- Robinson DR, Yi-Mi Q, Su-Fang L. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–5557. - PubMed
- Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut. 2010;59:838–858. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous